OPTIMOX-bevacizumab

BIOLOGICAL2 trials

Sponsors

GERCOR - Multidisciplinary Oncology Cooperative Group

Conditions

Colorectal Cancer MetastaticElderly PatientsMetastatic Colorectal CancerQuality of Life

Phase 3

Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer

Active, not recruitingNCT01910610

GERCOR - Multidisciplinary Oncology Cooperative GroupColorectal Cancer Metastatic

Start: 2013-10-30End: 2024-12-31Updated: 2024-03-12

QoL in mCRC Elderly Patients Receiving First-line Therapy Based on Simplified Geriatric Parameters.

Active, not recruitingNCT03828227

GERCOR - Multidisciplinary Oncology Cooperative GroupElderly Patients, Metastatic Colorectal Cancer, Quality of Life

Start: 2019-06-14End: 2025-12-31Updated: 2025-07-18

Related Papers

STRATEGIC-1: multiple-line, randomized, open-label GERCOR-PRODIGE-39 phase III trial in unresectable RAS/BRAF wild-type metastatic colorectal cancer.

2026-04-14

STRATEGIC-1: Multi-line therapy trial in unresectable wild-type KRAS/NRAS/BRAF metastatic colorectal cancer—A GERCOR-PRODIGE randomized open-label phase III study.

Journal of Clinical Oncology2022-06-019 citations

STRATEGIC-1: A multiple-lines, randomized, open-label GERCOR phase III study in patients with unresectable wild-type RAS metastatic colorectal cancer.

2015-07-0417 citations

Strategic 1-multi-line therapy trial in unresectable wild-type RAS metastatic colorectal cancer : A gercor randomized open-label phase III study.

Journal of Clinical Oncology2014-05-203 citations